BTIG Research Issues Pessimistic Forecast for Stryker (NYSE:SYK) Stock Price

Stryker (NYSE:SYK) had its target price lowered by equities research analysts at BTIG Research from $371.00 to $358.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the medical technology company’s stock. BTIG Research’s price target would indicate a potential upside of 2.76% from the company’s current price.

Other research analysts also recently issued reports about the company. Argus set a $370.00 price target on Stryker in a report on Thursday, July 9th. Evercore set a $350.00 target price on Stryker in a research report on Monday, July 6th. Needham & Company LLC lowered their price target on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a report on Friday, May 1st. Weiss Ratings downgraded shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. Finally, Sanford C. Bernstein set a $410.00 target price on shares of Stryker in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus price target of $392.08.

Stryker Price Performance

Shares of NYSE SYK opened at $348.37 on Friday. The company’s fifty day moving average is $317.08 and its two-hundred day moving average is $334.98. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The firm has a market capitalization of $133.55 billion, a P/E ratio of 40.32, a PEG ratio of 2.26 and a beta of 0.77. Stryker has a one year low of $281.00 and a one year high of $401.99.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same period in the previous year, the business earned $3.13 earnings per share. Stryker’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Analysts forecast that Stryker will post 14.99 EPS for the current fiscal year.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 323,264 shares of company stock valued at $100,659,489. Corporate insiders own 4.60% of the company’s stock.

Institutional Trading of Stryker

A number of institutional investors and hedge funds have recently modified their holdings of the business. Brighton Jones LLC increased its position in Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after acquiring an additional 609 shares during the period. Schnieders Capital Management LLC. bought a new position in Stryker in the 2nd quarter valued at about $205,000. Marshall Wace LLP increased its stake in Stryker by 107.9% during the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after buying an additional 77,831 shares during the period. Nebula Research & Development LLC acquired a new position in shares of Stryker during the second quarter valued at approximately $219,000. Finally, HUB Investment Partners LLC bought a new stake in Stryker during the second quarter worth approximately $253,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker reported adjusted earnings of $3.69 per share, ahead of the $3.49 consensus estimate and up 17.9% year over year. Revenue increased 9.4% to $6.59 billion, while strong demand for orthopedic, spinal and other medical devices supported results. Stryker beats quarterly estimates on strong demand for medical devices
• Positive Sentiment: Second-quarter organic sales growth was 9%, and adjusted gross margin reached 66%. Management also said recovery from the cyberattack is progressing, helping ease concerns about disruption to orders, operations and customer service. Stryker Q2 2026 earnings call highlights
• Positive Sentiment: Stryker expects 2026 adjusted EPS of $14.95 to $15.10 and organic sales growth of 8.3% to 9.3%, broadly consistent with analyst expectations. The company also resumed share repurchases, adding potential support for per-share results. Stryker 2026 outlook and share repurchases
• Neutral Sentiment: UBS initiated research coverage with a Buy rating and a $400 price target, implying meaningful upside from the reported $348.37 opening level. Stryker coverage started at UBS Group
• Negative Sentiment: Revenue was only slightly above expectations, which may have disappointed investors given Stryker’s premium valuation and strong demand trends. The stock decreased as the earnings beat was viewed as insufficient to overcome elevated expectations. Stryker Q2 sales in line with estimates
• Negative Sentiment: Cyberattack recovery remains an execution risk. Although progress has been made, ongoing disruptions and related costs could weigh on near-term growth and margins.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.